Nuvation Bio (NUVB) Interest Expenses (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Interest Expenses of $6.7 million for Q1 2026, up 657.11% year-over-year from $886000.0 in Q1 2025, and down 33.83% quarter-over-quarter from $10.1 million in Q4 2025.
Nuvation Bio (NUVB) Interest Expenses (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Interest Expenses for 7 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 657.11% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $23.5 million (up 2548.87% YoY), while the FY2025 annual figure was $450.5 million, up 89.18% from the prior year.
- Interest Expenses declined to $6.7 million in Q1 2026 per NUVB's latest filing, from $10.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $10.1 million in Q4 2025 and bottomed at $89000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $4.6 million across 5 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Interest Expenses slumped 78.7% — and 2025, when it surged 11291.01%.
- Nuvation Bio's Interest Expenses stood at $5.6 million in 2022, then tumbled by 40.36% to $3.3 million in 2023, then tumbled by 97.34% to $89000.0 in 2024, then soared by 11291.01% to $10.1 million in 2025, then slumped by 33.83% to $6.7 million in 2026.
- Business Quant data shows NUVB's Interest Expenses at $6.7 million in Q1 2026, $10.1 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 6.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.76 Mn |
| Jun 30, 2026 | 6.76 Mn |
| Mar 31, 2026 | 6.71 Mn |
| Mar 31, 2026 | 6.71 Mn |
| Dec 31, 2025 | 10.14 Mn |
| Dec 31, 2025 | 10.14 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 886,000.00 |
| Mar 31, 2025 | 886,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Sep 30, 2024 | 713,000.00 |
| Sep 30, 2024 | 713,000.00 |
| Jun 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.76 Mn |